In 3Q17, Merck’s (MRK) Bridion reported revenue of $185 million, which reflected ~33% growth YoY (year-over-year) and 13% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Bridion generated revenue of $495 million, which reflected 44% growth YoY. Growth in US sales volumes primarily contributed to the drug’s revenue growth in the two periods.
In 3Q17, Noxafil generated revenue of $162 million, which is ~10% growth YoY and ~5% growth QoQ. Noxafil is an antifungal agent used for prophylaxis against fungal infections in individuals with weak immune systems.
In 3Q17, Invanz reported revenue of $159 million, which is ~5% growth YoY and 6% growth QoQ. During the first nine months of 2017, Invanz generated revenue of $445 million, which reflected ~9% growth YoY. Higher pricing in the US market and favorable foreign exchange effects primarily contributed to Invanz’s revenue growth in 3Q17 and the first nine months of 2017.
In 3Q17, Cancidas generated revenue of $94 million, which reflected a ~34% fall YoY and a 16% fall QoQ. Cancidas is primarily sold outside the US market. During the first nine months of 2017, it saw revenue of $327 million, which reflected ~19% growth YoY. Cancidas is an antifungal agent.
In 3Q17, Cubicin generated revenue of ~$91 million, which is a ~72% fall YoY and a ~12% fall QoQ. During the first nine months of 2017, Cubicin generated revenue of $290 million, which is a ~70% fall YoY. Merck anticipates the generic competition with Cubicin to continue, as the drug’s US composition patent expired in June 2016.
In 3Q17, Primaxin reported revenue of $73 million, which is a ~5% fall YoY and 3% growth QoQ. Primaxin (imipenem and cilastatin) is indicated for the treatment of bacterial infections.
In 3Q17, Merck’s acute hospital care drug peers, Teva Pharmaceutical (TEVA), GlaxoSmithKline (GSK), and Johnson & Johnson (JNJ), reported revenue of $5.6 billion, $7.8 billion, and $19.7 billion, respectively. Notably, the PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) invests ~4.3% and 5.2%, respectively, of its total portfolio in Merck and Johnson & Johnson.